$DexCom (DXCM.US)$It plummeted by more than 40% in the intraday session on Friday, and is now down 40.54% to $64.13, with a turnover of over $1.1 billion.

Financial results released after the market on July 25

Dekang Healthcare's EPS for the second quarter was $0.35, compared to $0.28 for the same period in 2023. Second-quarter revenue was $1 billion, and analysts expected $1.04 billion. The annual revenue is expected to be 4 billion-4.05 billion US dollars, and the company originally expected 4.2 billion-4.35 billion US dollars. The adjusted gross profit margin for the full year was expected to be 63%, analysts expected 63.4%, and the company originally expected 63%-64%.

Third-quarter revenue is expected to be around 0.975 billion to $1 billion.

The company also announced a $0.75 billion share repurchase program in conjunction with its second-quarter results.

Wall Street analysts have mixed reviews

• According to J.P. Morgan Chase, the company's new customer launch rate in the second quarter was lower than expected, per capita revenue from US customers fell faster than expected, international business performance was also lower than expected, and there is no indication that the weakness of Dekang Healthcare was caused by GLP-1s (continuous blood sugar monitors designed and sold by Dekang Healthcare).

• J.P. Morgan downgraded Decon Healthcare to a neutral rating and lowered the target price to $75. Morgan Stanley downgraded Dekang Medical's target price from 160 Xiaomao to a neutral rating, and lowered the target price to 75 US dollars.

• Baird analyst Jeff Johnson downgraded Dekang Healthcare's rating from buying to neutral and lowered its price target from $161 to $80. He believes that the path ahead is too unclear, and advises not to buy at a low level.

• William Blair analyst Margaret Kaczor Andrew is more optimistic, maintaining the stock's outperforming market rating. I think the problems the company is experiencing are within control.

• Raymond James analysts Jayson Bedford and Glenn Shell also assessed the performance and lowered the stock price target from $160 to $115, but reiterated the buy rating. “The quarterly results were disappointing, but the company is still expected to benefit from the continuous blood sugar monitoring market, which is growing at a moderate rate.”